Search Results for "Infection"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Infection. Results 411 to 420 of 851 total matches.
Autologous Bone marrow Transplantation For Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • May 03, 1991 (Issue 843)
of infection before
the bone marrow recovers. Autologous transplants are less dangerous than allogeneic ...
The prognosis in breast cancer is generally poor for women with unresectable, locally advanced disease (inflammatory cancer or more than 10 positive lymph nodes) and for those with metastases. Autologous bone marrow transplantation - removing bone marrow from multiple sites under general anesthesia, giving high-dose chemotherapy with or without total body radiation, and reinfusing the bone marrow intravenously - is being tried in some of these patients.
Tetramune - A Combined Vaccine For Infants
The Medical Letter on Drugs and Therapeutics • Nov 12, 1993 (Issue 909)
Haemophilus influenzae type b infection and
hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now ...
The number of immunizations recommended for infants and young children has increased in recent years with the addition of vaccines to prevent Haemophilus influenzae type b infection and hepatitis B (Medical Letter, 33:5, 1991; 34:69, 1992). Now the US Food and Drug Administration has licensed a new vaccine for infants (Tetramune - Lederle-Praxis) that combines a traditional diphtheria, tetanus, and pertussis vaccine (DTP; Tri-Immunol) with a vaccine against Haemophilus influenzae type b (HibTiter).
Homeopathic Products
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
Vickers et al, Clin J Pain, 14:227, 1998) or prevention of upper respiratory infections in children (ESM ...
Some patients may ask physicians about the effectiveness and safety of homeopathic drugs, which are marketed through health food stores, pharmacies, direct mail and person-to-person sales, and promoted for use in a wide range of disorders.
In Brief: Measles Outbreak
The Medical Letter on Drugs and Therapeutics • Jun 02, 2008 (Issue 1287)
Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases ...
The US Centers for Disease Control and Prevention (CDC) has reported that measles outbreaks have occurred in New York City, California and Arizona in 2008, and additional cases have been confirmed in Michigan, Wisconsin, Hawaii, New York State, Pennsylvania, Illinois and Virginia (CDC Health Advisory, May 1, 2008). To date, 63 of the 64 infected patients were unvaccinated, and 54 of the cases were associated with importation of the disease. Both measles infection and vaccination (2 doses at least 28 days apart, with the first dose no earlier than 12 months of age) generally provide lifelong...
Tribenzor for Hypertension
The Medical Letter on Drugs and Therapeutics • Sep 06, 2010 (Issue 1346)
,
nausea, upper respiratory infection, diarrhea, urinary
tract infection and joint swelling. Tribenzor ...
Many patients with hypertension require more than one drug to control their blood pressure. Tribenzor (Daiichi Sankyo), recently approved by the FDA for treatment of hypertension, combines the calcium channel blocker amlodipine (Norvasc, and others), the angiotensin receptor blocker (ARB) olmesartan (Benicar)and the most commonly prescribed diuretic, hydrochlorothiazide (HCTZ). Tribenzor is not approved for initial therapy, but is recommended for patients not adequately controlled on any 2-drug combination of a calcium channel blocker, an ARB or a diuretic.
SGLT2 Inhibitors: New Reports
The Medical Letter on Drugs and Therapeutics • Oct 12, 2015 (Issue 1479)
pressure.
Adverse Effects – SGLT2 inhibitors can cause genital
mycotic infections, urinary tract ...
The recent report of a reduction in cardiovascular
mortality in patients with type 2 diabetes treated with
the SGLT2 inhibitor empagliflozin (Jardiance) was
published soon after the FDA issued new warnings
about an increased risk of fractures with canagliflozin
(Invokana).
Zarxio - A Filgrastim Biosimilar
The Medical Letter on Drugs and Therapeutics • Mar 14, 2016 (Issue 1490)
of infection‚ as manifested by febrile
neutropenia‚ in patients with nonmyeloid malignancies receiving ...
The FDA has approved filgrastim-sndz (Zarxio –
Sandoz), a biosimilar of the recombinant human
granulocyte colony-stimulating factor filgrastim
(G-CSF; Neupogen), which has been available in the
US since 1991. Zarxio is the first biosimilar product to
be approved in the US; it has been available in Europe
as Zarzio since 2009.
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
infection, and upper respiratory
tract infection.
DRUG INTERACTIONS — Neratinib is metabolized primarily ...
The oral tyrosine kinase inhibitor neratinib (Nerlynx –
Puma Biotechnology) has been approved by the FDA
for use in combination with capecitabine (Xeloda, and
generics) for treatment of advanced or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior
anti-HER2-based regimens for metastatic disease.
It was previously approved for use as monotherapy
for extended adjuvant treatment of adults with early-stage,
HER2-positive breast cancer following adjuvant
trastuzumab (Herceptin)-based therapy. HER2 is
overexpressed in...
In Brief: Zanubrutinib (Brukinsa) for CLL or SLL (online only)
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
, particularly atrial
fibrillation, infection, rash, and bleeding, that may
be related to inhibition of kinases ...
The Bruton's tyrosine kinase (BTK) inhibitor
zanubrutinib (Brukinsa), which was previously
approved by the FDA for treatment of mantle cell
lymphoma, Waldenström's macroglobulinemia,
and relapsed or refractory marginal zone
lymphoma, has now been approved for treatment
of chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL) in adults. The BTK
inhibitors ibrutinib (Imbruvica) and acalabrutinib
(Calquence) were approved earlier for treatment of
CLL and SLL.
Med Lett Drugs Ther. 2023 Feb 20;65(1670):e33-4 doi:10.58347/tml.2023.1670e | Show Introduction Hide Introduction
Expanded Table: Some Vaccines for Travelers (online only)
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
conditions,
blood type O, low gastric acidity) if
infected
▶ For most tourists, the risk of exposure ...
View the Expanded Table: Some Vaccines for Travelers